Thank you for donating!

You can donate using the following services.


  1. 20.01.21

    MNK Announcement Jan 2021

    We have received the following statement from Mallinckrodt Pharmaceuticals, stating their intention to discontinue clinical development of adrabetadex (VTS-270) for Niemann-Pick Type C1 disease (NPC), effective immediately. We understand that this will be very difficult news for many within our community; the NPUK team will be available if you would like to contact us: email or telephone 0191 415 06 93.

    Read more
  2. 19.01.21

    UK Disability Survey

    The government has just announced a new UK Disability Survey and we want to hear from as many people as possible. They are particularly keen to hear from disabled people, their carers, friends and family but views from the wider public are also very welcome. The survey will remain open until 23rd April, and all views will be used to shape the delivery of the plans we set out in the Strategy with those that we receive by 13th February informing its development.

    Read more
  3. 05.01.21

    Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol® Cyclo™ in Patients with Niemann-Pick Disease Type C

    Home-based intravenous infusions of Trappsol® Cyclo™ for up to one year show improvement in disease features or disease stabilization...

    Read more
  4. 05.01.21

    NPUK 2020 Support Fund

    In recognition that many in our community are being impacted by the events of 2020, Trustees of NPUK and The Hollie Foundation, in recognition of their shared goals, have designated funds to create a new grant scheme for patients and families. The aim of this fund is to assist those experiencing hardship or unexpected expense, which threatens to impact their physical or mental well-being...

    Read more
  5. 28.12.20

    Orphazyme Provides Regulatory Update on Arimoclomol for NPC

    Read more